FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256355871> ?p ?o ?g. }

• W4256355871 abstract "Methotrexate, a disease-modifying antirheumatic drug, is fundamental to limiting progression in several rheumatic diseases such as rheumatoid arthritis (RA). However, methotrexate is also associated with various significant adverse effects. Of note, there are several dermatologic manifestations attributed to methotrexate therapy. In particular, accelerated nodulosis and panniculitis are linked to methotrexate therapy in the current literature. The authors present the case of a 55-year-old Caucasian female with seropositive erosive RA who developed superficial ulcerating rheumatoid necrobiosis (SURN), secondary to methotrexate therapy. The patient’s treatment consisted of methotrexate discontinuation, topical clobetasol, and initiation of leflunomide as a replacement of methotrexate. Follow-up evaluation confirmed resolution of SURN over time and maintained low disease RA activity with leflunomide.Few cases describe SURN in the setting of RA and there are currently no cases published that suggest methotrexate’s possible role in SURN. Methotrexate-induced SURN is plausible in this case because of the correlation with therapy initiation and remission after therapy discontinuation. SURN has significant histological overlap with other methotrexate-induced dermatologic manifestations, allowing for a possible correlation. Most dermatological side effects of methotrexate are linked to a genetic predisposition of the HLA-DRB1 gene. Additionally, methotrexate’s mechanism of action for rheumatologic disease paradoxically stimulates adenosine-1 receptors and activates neutrophil chemotaxis and phagocytosis. Adenosine-1 receptor stimulation is hypothesised to be the source of rheumatoid-accelerated nodulosis and possibly SURN. Furthermore, the location of manifestation, genetic predisposition, and comorbid features in the patient all possibly have a role in this unique dermatological side effect." @default.
• W4256355871 created "2022-05-12" @default.
• W4256355871 creator A5011715488 @default.
• W4256355871 creator A5037203566 @default.
• W4256355871 creator A5046470122 @default.
• W4256355871 creator A5072253769 @default.
• W4256355871 creator A5089463394 @default.
• W4256355871 creator A5091249299 @default.
• W4256355871 date "2020-09-17" @default.
• W4256355871 modified "2023-10-16" @default.
• W4256355871 title "Superficial Ulcerating Rheumatoid Necrobiosis Associated with Methotrexate Use in a Patient with Rheumatoid Arthritis" @default.
• W4256355871 cites W1963628169 @default.
• W4256355871 cites W2024974548 @default.
• W4256355871 cites W2025001196 @default.
• W4256355871 cites W2029492895 @default.
• W4256355871 cites W2077323523 @default.
• W4256355871 cites W2117764489 @default.
• W4256355871 cites W2154362046 @default.
• W4256355871 cites W2157940881 @default.
• W4256355871 cites W2569008466 @default.
• W4256355871 cites W2767663220 @default.
• W4256355871 cites W2891474673 @default.
• W4256355871 cites W2947072611 @default.
• W4256355871 cites W3091089997 @default.
• W4256355871 cites W4243799321 @default.
• W4256355871 cites W4250639022 @default.
• W4256355871 doi "https://doi.org/10.33590/emj/20-00066" @default.
• W4256355871 hasPublicationYear "2020" @default.
• W4256355871 type Work @default.
• W4256355871 citedByCount "0" @default.
• W4256355871 crossrefType "journal-article" @default.
• W4256355871 hasAuthorship W4256355871A5011715488 @default.
• W4256355871 hasAuthorship W4256355871A5037203566 @default.
• W4256355871 hasAuthorship W4256355871A5046470122 @default.
• W4256355871 hasAuthorship W4256355871A5072253769 @default.
• W4256355871 hasAuthorship W4256355871A5089463394 @default.
• W4256355871 hasAuthorship W4256355871A5091249299 @default.
• W4256355871 hasBestOaLocation W42563558711 @default.
• W4256355871 hasConcept C126322002 @default.
• W4256355871 hasConcept C16005928 @default.
• W4256355871 hasConcept C197934379 @default.
• W4256355871 hasConcept C203014093 @default.
• W4256355871 hasConcept C2775905006 @default.
• W4256355871 hasConcept C2777575956 @default.
• W4256355871 hasConcept C2778715236 @default.
• W4256355871 hasConcept C2781059491 @default.
• W4256355871 hasConcept C71924100 @default.
• W4256355871 hasConceptScore W4256355871C126322002 @default.
• W4256355871 hasConceptScore W4256355871C16005928 @default.
• W4256355871 hasConceptScore W4256355871C197934379 @default.
• W4256355871 hasConceptScore W4256355871C203014093 @default.
• W4256355871 hasConceptScore W4256355871C2775905006 @default.
• W4256355871 hasConceptScore W4256355871C2777575956 @default.
• W4256355871 hasConceptScore W4256355871C2778715236 @default.
• W4256355871 hasConceptScore W4256355871C2781059491 @default.
• W4256355871 hasConceptScore W4256355871C71924100 @default.
• W4256355871 hasLocation W42563558711 @default.
• W4256355871 hasLocation W42563558712 @default.
• W4256355871 hasOpenAccess W4256355871 @default.
• W4256355871 hasPrimaryLocation W42563558711 @default.
• W4256355871 hasRelatedWork W15191088 @default.
• W4256355871 hasRelatedWork W15635221 @default.
• W4256355871 hasRelatedWork W16684612 @default.
• W4256355871 hasRelatedWork W16961017 @default.
• W4256355871 hasRelatedWork W19323031 @default.
• W4256355871 hasRelatedWork W19650924 @default.
• W4256355871 hasRelatedWork W20616117 @default.
• W4256355871 hasRelatedWork W3725601 @default.
• W4256355871 hasRelatedWork W8944291 @default.
• W4256355871 hasRelatedWork W9853369 @default.
• W4256355871 isParatext "false" @default.
• W4256355871 isRetracted "false" @default.
• W4256355871 workType "article" @default.